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Autoimmune diseases are more common in dogs than in humans and are already 
threatening the future of some highly predisposed dog breeds. Susceptibility to 
autoimmune diseases is controlled by environmental and genetic factors, especially the 
major histocompatibility complex (MHC) gene region. Dogs show a similar physiology, 
disease presentation and clinical response as humans, making them an excellent disease 
model for autoimmune diseases common to both species. The genetic background of 
canine autoimmune disorders is largely unknown, but recent annotation of the dog genome 
and subsequent development of new genomic tools offer a unique opportunity to map 
novel autoimmune genes in various breeds. Many autoimmune disorders show breed-
specific enrichment, supporting a strong genetic background. Furthermore, the presence of 
hundreds of breeds as genetic isolates facilitates gene mapping in complex autoimmune 
disorders. Identification of novel predisposing genes establishes breeds as models and may 
reveal novel candidate genes for the corresponding human disorders. Genetic studies will 
eventually shed light on common biological functions and interactions between genes and 
the environment. 
This study aimed to identify genetic risk factors in various autoimmune disorders, 
including systemic lupus erythematosus (SLE)-related diseases, comprising immune-
mediated rheumatic disease (IMRD) and steroid-responsive meningitis arteritis (SMRA) 
as well as Addison’s disease (AD) in Nova Scotia Duck Tolling Retrievers (NSDTRs) and 
chronic superficial keratitis (CSK) in German Shepherd dogs (GSDs). We used two 
different approaches to identify genetic risk factors. Firstly, a candidate gene approach 
was applied to test the potential association of MHC class II, also known as a dog 
leukocyte antigen (DLA) in canine species. Secondly, a genome-wide association study 
(GWAS) was performed to identify novel risk loci for SLE-related disease and AD in 
NSDTRs. 
We identified DLA risk haplotypes for an IMRD subphenotype of SLE-related disease, 
AD and CSK, but not in SMRA, and show that the MHC class II gene region is a major 
genetic risk factor in canine autoimmune diseases. An elevated risk was found for IMRD 
in dogs that carried the DLA-DRB1*00601/DQA1*005011/DQB1*02001 haplotype (OR 
= 2.0, 99% CI = 1.03-3.95, p = 0.01) and for ANA-positive IMRD dogs (OR = 2.3, 99% 
CI = 1.07-5.04, p-value 0.007). We also found that DLA-
DRB1*01502/DQA*00601/DQB1*02301 haplotype was significantly associated with AD 
in NSDTRs (OR = 2.1, CI = 1.0-4.4, P = 0.044) and the DLA-
DRB1*01501/DQA1*00601/DQB1*00301 haplotype with the CSK in GSDs (OR=2.67, 
CI=1.17-6.44, p= 0.02). In addition, we found that homozygosity for the risk haplotype 
increases the risk for each disease phenotype and that an overall homozygosity for the 
DLA region predisposes to CSK and AD. Our results have enabled the development of 
genetic tests to improve breeding practices by avoiding the production of puppies 
homozygous for risk haplotypes. 
We also performed the first successful GWAS for a complex disease in dogs. With less 
than 100 cases and 100 controls, we identified five risk loci for SLE-related disease and 
AD and found strong candidate genes involved in a novel T-cell activation pathway. We 
show that an inbred dog population has fewer risk factors, but each of them has a stronger 




genetic risk. Ongoing studies aim to identify the causative mutations and bring new 
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Autoimmune diseases occur when an adaptive immune response develops against self-
antigens, causing inflammation that may lead to tissue damage. Expression of 
autoimmunity can be organ-specific, as in type 1 diabetes mellitus affecting pancreatic 
islets, or systemic, as in systemic lupus erythematosus (SLE), which affects multiple 
tissues 
1
. Susceptibility to autoimmune diseases is controlled by environmental and 
genetic factors, especially major histocompatibility complex (MHC) class II alleles 
2
. 
More than 60% of canine inherited diseases are shared with humans
 
and the coding 
sequences of dogs and humans show ~90% similarity. Dogs are large animals, share a 
living environment with humans and show similar physiology, disease presentation and 




Tight bottle necks in the population history of a domestic dog, such as breed creation, 
World War II, infection outbreaks and modern breeding practices relying on popular sires 
and tight inbreeding, have accumulated different genetic risk factors and diseases in dog 
breeds. Dog breeds consist of genetically similar individuals and resemble isolated human 
populations, such as Finns and Icelanders, that are widely used in genetic studies 
7,8
. 
Observed as a group, dogs show the same extensive genetic diversity as humans, or 
ancient wolves. At the genome level, this can be seen as long haplotype blocks within a 
breed and short across breed. Extensive linkage disequilibrium within a breed enables the 
use of genetic markers, such as single-nucleotide polymorphisms (SNPs) in genome-wide 
association studies (GWAS) with a small number of samples and markers. Ancient 
mutations may have segregated into related breeds showing the same disease phenotype, 
and as the haplotype blocks are short between the breeds, related breeds can be used to 
narrow down (fine-mapping) and verify the associated loci between a marker and a 
phenotype 
9,10
. This two-stage strategy has been successfully used to identify several 
Mendelian traits such as white coat colour 
11
, the hair ridge that causes predisposition to 
dermoid sinus 
12
, recessive cone-rod dystrophy 
13
 and ectodermal dysplasia 
14
. 
Several breeds are highly susceptible to autoimmune diseases. Nova Scotia Duck 
Tolling Retrievers (NSDTRs) have been recognized to have a strong genetic 
predisposition to several autoimmune diseases, including immune-mediated rheumatic 
disease (IMRD) 
15
, steroid-responsive meningitis arteritis (SRMA) 
16,17
, 
hypoadrenocorticism (Addison’s disease, AD) 
18
 and canine lymphocytic thyroiditis 
(CLT) 
19
. IMRD and SRMA may be a part of the same disorder, canine systemic lupus 
erythematosus (SLE)-related disease complex. German Shepherd dogs (GSDs) are over-
represented with chronic superficial keratitis (CSK) 
20
 and reported to show also 









 and myasthenia gravis (MG) 
26
. 
Regardless of the high prevalence of autoimmune disorders in dogs, the genetic 







, canine primary immune-mediated 
haemolytic anaemia (IMHA) 
30
 and canine rheumatoid arthritis (CRA) 
31
. In this study, we 
focused on the characterization of the genetic risk factors in particular autoimmune 
diseases in two breeds of dog including SLE-related diseases, comprising IMRD and 




SRMA, AD and CSK. No previous genetic studies have been reported in any of these 
diseases, although an autoimmune origin has been suspected in each disorder. Utilizing 
novel genomic tools and candidate and genome-wide approaches, we mapped several new 
genetic risk loci. This study establishes novel canine models for human autoimmune 









2 Review of the literature 
2.1 Autoimmune disorders 
2.1.1 Overview of innate and adaptive immunology 
The role of the immune system is to protect the host from invading pathogens. The innate 
immune system is present at birth and lacks of memory and strict recognition of antigen. 
In its simplest form, the innate immune system comprises anatomical and physiological 
barriers, such as skin, mucous membranes, and temperature, pH and oxygen levels. 
Soluble components of the innate immune system include digestive enzymes, such as 
lysozyme in tears, peptides that bind essential nutrients, such as iron-binding lactoferrin in 
a mammary gland, and the complement system, an enzymatic protein cascade that 
produces various chemoattractants, inflammatory mediators, opsonins and a hole-
punching complex capable of disrupting membrane structures. Cytokines and chemokines 
secreted by many cells, including the epithelial cells, mediate intercellular communication 
and initiate a variety of signalling pathways 
1,32
. 
The cellular components of the innate immune system include cytotoxic cells, 
neutrophils, eosinophils, basophils and mast cells. Neutrophils and eosinophils are also 
phagocytic cells. Macrophages are phagocytic cells in the tissues and dendritic cells in 
tissues and lymphatic organs. Macrophages and dendritic cells serve as antigen-presenting 
cells (APCs). Antigenic peptides are presented in association with major 
histocompatibility complex (MHC) class I or II molecules to cytotoxic or helper T-
lymphocytes, respectively. Natural killer (NK) cells are lymphocytes without specific 
antigen recognition capability and induce apoptosis in altered cells. NK cells have recently 
been shown to have a memory, which suggests that they may be an evolutionary bridge 
between the innate and adaptive immune systems 
33
. Although phagocytic cells lack 
specific recognition of antigen, they do identify certain pathogen-associated molecular 




The adaptive immune system develops after birth and possesses a memory, enabling a 
heightened immune response to previously encountered antigens. Lymphocytes 
specifically recognize the foreign antigen and are divided into different types based on the 
mechanism of antigen recognition and effector functions. Specificity is achieved during 
lymphocyte development through a gene rearrangement, a somatic DNA recombination of 
gene segments encoding the variable (V) region of the antigen receptor. B-cells develop in 
bone marrow and produce a great variety of antigen receptors called immunoglobulins 
(Igs). All Igs are identical in a single cell and recognize a specific antigen. Igs expressed 
on a B-cell surface are called B-cell receptors (BCRs) and Igs with the same antigen 
specificity that are secreted by plasma cells as soluble form are called antibodies (abs).  
Isotype or class of the ab is determined by the heavy (H) chain and in part directs the 
function following the activation 
1,32
. 




T-lymphocytes also develop in bone marrow, but mature in the thymus. The antigen 
receptors on T-cells are always membrane-bound and called T-cell receptors (TCRs). The 
structure and generation of antigen specificity are identical to that of B-cells and their 
function is to signal activation. The major difference is the recognition of antigen. TCRs 
can only bind antigens associated with the self MHC molecules. T-lymphocytes are 
divided into two subtypes based on function and cell surface markers. Cytotoxic T-cells 
(TC) express CD8 glycoprotein and induce apoptosis in altered cells. T-helper 
lymphocytes (TH) express CD4 cell marker and modulate immune response primarily 
through cytokine secretion. TH cells can further be divided into TH1, TH2, TH17 and 
regulatory T-cells (Treg). TH1 cells secrete interferon-  (IFN- ) and tumour necrosis factor 
 (TNF- ). They promote elimination of intracellular pathogens, and cell-mediated and 
delayed-type hypersensitivity responses. TH2 cells secrete interleukins (IL) IL-4 and IL-5, 
which contribute to allergic responses and the clearance of extracellular pathogens, such 
as worms, and promote humoral response. TH17 cells secrete IL-17 and IL-22, which are 
important cytokines in fighting extracellular bacteria and fungi. Treg cells express CD25 as 
well as CD4 cell marker and are suppressive mediators of immune responses as well as 
important in maintaining peripheral tolerance 
34
. 
The lymphocyte-antigen encounter takes place in secondary lymphoid tissue and leads 
to activation through changes in gene expression, proliferation and differentiation into 
effector cells. After encountering an antigen, B-cells differentiate into plasma and memory 
cells. Plasma cells secrete antibodies, which neutralize extracellular pathogens by coating, 
agglutinating and opsonizing them. Perhaps most importantly, they activate the 
complement cascade. TC cells induce apoptosis in target cells by releasing the content of 
cytoplasmic granules and/or by expressing a transmembrane protein Fas-ligand. TH cells 
direct the immune response towards humoral or cell-mediated response by secreting 
cytokines. Treg cells secrete cytokines that modulate the function of dendritic cells and 
lymphocytes and even induce apoptosis in the latter 
34,35
. 
Many vital organs regarding survival and reproduction, which possess limited capacity 
for regeneration, are considered to be immune privilege body sites. These organs include 
the brain, cornea, testes and the pregnant uterus. However, recent evidence suggests that 
immune privilege is not a global suppression of all immune responses but in fact an active 
and closely regulated adaptation of the immune system with the objective of protecting 
organs from immune-mediated damage. Most harmful immune responses are down-
regulated, while others, less harmful, are preserved. Anterior chamber-associated immune 
deviation (ACAID) is an example of this kind of regional immunity 
36
. After encountering 
an antigen, the APCs travel directly to the spleen, where they interact with other cells of 
the immune system, resulting in activation of TH1-suppressing Treg cells 
37
. Brain-












2.1.2 Overview of autoimmunity 
The ability to differentiate self from foreign is an essential basis in avoiding immune-
mediated damage to self-tissue. A central tolerance is introduced during foetal 
development in bone marrow and thymus by negative selection, resulting in apoptosis of 
strongly self-reactive lymphocytes. Autoimmune diseases occur when the self-tolerance is 
lost and an adaptive immune response develops against self-antigens 
1,38
. Autoimmune 
regulator (AIRE) is a transcription factor that promotes expression of tissue-specific 
antigens in thymic medullary cells, enabling the formation of self-peptide-MHC 
complexes. The CD4+CD8+ (double-positive, DP) thymocytes, derived from bone 
marrow haematopoietic precursors, interact with these cortical epithelial cells, enabling 
the negative selection of too strongly binding T-cells. Thymocytes that interact with 
appropriate affinity with peptide-MHC class I complexes become CD8+ T-cells, while 
those that interact with peptide- MHC class II complexes become CD4+ T-cells 
39
. As 
important are mechanisms maintaining peripheral tolerance, which eliminate or inactivate 
the potentially autoreactive T-cells that have escaped negative selection. These include the 
loss of suppression of Tregs 
40
. 
Organ-specific autoimmune pathogenesis has primarily been associated with TH1, but 
not TH2 cells. In some systemic autoimmune diseases, like SLE, TH2 cells have been 
shown to have an influence, but they are not considered the driving force. Recently 
identified TH17 cells have been demonstrated to have a major role in autoimmunity and 
Treg cells in preventing immune-mediated damage. The balance and interplay of all of 
these T-cell subtypes with each other are critical for developing autoimmune diseases 
40
. 
A constant concentration of autoantigens and the lack of their eradication them makes 
autoimmune diseases chronic. Chronic inflammation gives positive feedback by attracting 
macrophages and neutrophils by secreted cytokines and chemokines and by revealing new 
autoantigens from damaged tissues, a phenomenon called epitope spreading. Epitope 
spreading may explain the relapses common to many autoimmune diseases 
1,38
. 
The autoimmune diseases may be organ-specific, affecting limited tissues, or systemic, 
with autoimmunity being expressed in several tissues. In systemic autoimmune diseases, 
such as in SLE, non-organ specific autoantibodies attack ubiquitous self-molecules. In 
SLE, the main target is chromatin. In organ-specific autoimmune diseases, the target 
antigens are found in one or a few organs and the tissue destruction is limited to these 
organs, although there may be symptoms affecting the whole body, such as fever 
1
. Canine 
organ-specific autoimmune disorders include several diseases affecting the haematologic 
system, such as IMHA, immune-mediated thrombocytopenia (IMTP) and immune-
mediated neutropenia 
38
. Also several autoimmune diseases of the endocrine system have 
been characterized, such as autoimmune thyroiditis, autoimmune diabetes mellitus and 
AD. Autoimmune diseases affecting the skin include discoid lupus and bullous skin 
diseases and those affecting the the musculoskeletal system, MG and CRA. Ocular 
autoimmune diseases are e.g. canine uveodermatologic syndrome or Vogt-Koyanagi-
Harada –like syndrome (VKH-like) and CSK 
38,41
. 




2.1.3 Genetic background of autoimmune diseases 
A few autoimmune syndromes exist where a single gene is a causative risk factor, such as 
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) 
42,43
. In 
APECED, the transcription factor gene, AIRE, is defective, causing the destruction of 
multiple endocrine tissues. Still, most of the autoimmune disorders are thought to be 
polygenic, and several genes and pathways have already been identified in humans. These 
susceptibility genes are often involved in autoantigen availability and clearance, apoptosis, 
signalling, cytokine gene expression and expression of co-stimulatory molecules. Genetics 
studies in canine autoimmune diseases have to date revealed several associations with the 
MHC class II locus. As yet, few other genetic risk factors outside the MHC class II region 
have been identified in canine autoimmune diseases 
44
. This is not the case in human 
autoimmune diseases, where several genes have been identified. Some of these are 
presented in Table 1.  New array and sequencing technology is likely to reveal new genes 
and pathways also behind canine autoimmune diseases in the near future. 
Copy number variations (CNVs) are structural variations in a genome from one 
kilobase to several megabases in length. CNVs are rarer than SNPs, but are often located 
in gene areas, causing more likely changes in gene expression levels, disruption of gene 
dosage, unmasking of recessive alleles or regulatory polymorphism and loss of regulatory 
elements 
45-48
. Several CNVs are known to be associated to common diseases in humans, 
including cancer, neuropsychiatric diseases, infectious diseases and autoimmune diseases, 
SLE being one of them 
46,49
. DNA structural variation has been mapped in dogs, and it is 




Epigenetic modifications describe inherited changes in the expression of DNA that 
result from reasons other than what is coded in a DNA sequence. These include DNA 
methylation, chromatin remodelling, such as post-translational modifications of the 
histone proteins and RNA interference 
50
. Several acetylated proteins, have been 




2.1.3.1 Major histocompatibility complex (MHC) 
MHC is a multigene family found in all vertebrates studied to date. The human MHC 
region, also known as human leucocyte antigen (HLA) region, is located on chromosome 
6p21 and extends over 3.6 Mb. MHC region is divided into three subregions, MHC classes 
I, II and III. Canine MHC or DLA is a 3.9 Mb gene cluster mainly located on chromosome 
12. The MHC in carnivore species was split perhaps over 55 million years ago into two 
pieces within the TRIM (member of the tripartite motif) gene family found in HLA. DLA 
class II, III, and I regions were situated in a pericentromeric region of chromosome 12, 
whereas the remaining region was located in a subtelomeric region of chromosome 35. In 
addition, two class I genes are found on chromosomes 7 and 18 
52
 (Figure 1). Comparing 
mammalian species, it can be seen that chromosome breaks, inversion and/or centromere 










Figure 1 Genomic structure of human, mouse and dog major histocompatibility 




The MHC region encodes several genes involved in both the innate and adaptive 
immune system. The primary function of the MHC is to recognize, bind and transport 
antigens to the surfaces of APCs, where they are presented to T-cells 
1,54
. MHC class III 
encodes the complement pathway genes, cytokines TNF-  and –  and heat shock proteins. 
MHC class I and II encode genes that recognize, bind and present antigen peptides to 
cytotoxic CD8+ and helper CD4+ T-cells, respectively. This interaction between the APC 
and T-cell initiates the cellular and humoral immune response. MHC class I is expressed 
on all nucleated cells and binds endogenously produced peptides. Class II is expressed on 
APCs, such as macrophages, B-lymphocytes and dendritic cells, and presents exogenous 
material that was endo- or phagocytosed. Under inflammation, also fibroblasts and 
vascular endothelial cells may express MCH class II molecules. MHC class I and II are 




The DLA class II region includes four loci, DLA-DRB1, -DRA, -DQA1 and -DQB1, 
with one functional gene at each locus. All DLA class II genes, except DRA, are highly 
polymorphic. The polymorphism in the DLA region is genetically maintained by point 
mutations, genetic recombination and gene conversion. Research for new variants is 
ongoing, and to date 148 DLA-DRB1, 70 DLA-DQA1 and 26 DLA-DQB1 alleles have 
been identified (Dr. LJ Kennedy, personal communication). Many of the alleles are breed-
specific and most breeds have a very limited diversity of alleles. In comparison, the human 
HLA-DRB1 gene has over 600 alleles. MHC class II molecules are composed of two 
heterodimeric transmembrane glycoprotein chains  and , each consisting of two 
domains. The  domains are encoded by DLA-DQA1 and DLA-DRA1 genes, and the  
domains by DLA-DQB1 and DLA-DRB1 genes. The 1 and 1 subunits form the peptide 
binding groove (Figure 2).  






Figure 2 MHC class II protein. The  1 and 1 subunits form the peptide binding 
groove. 
SNP differences in second exons of the genes DLA-DRB1, DLA-DQA1 and DLA-
DQB1 create changes mostly in the hypervariable (HVR) regions of the peptide binding 
cleft, therefore altering the specificity of peptide recognition, binding and T-cell 
presentation. The DRB1 alleles are usually seen only with one combination with DQA1- 
and DQB1- alleles as the DQ alleles may be seen in combination with several different 
DRB1 alleles 
56
. These allele combinations or haplotypes may act epistaticly and provide 
some biological advantage as has been shown in human studies 
57
. 
There are several suggested mechanisms to maintain the polymorphisms in MHC 
region. These can be divided into two main models, the disease-based and reproductive 
mechanism. The disease-based model operates through balancing selection between host 
and pathogen and is based on their co-evolution. The heterozygote advantage hypothesis 
suggests that heterozygosity is favoured, as heterozygotes are able to present antigens 
more broadly. This hypothesis is also known as the overdominance/dominance hypothesis; 
the hetorozygote in the overdominance hypothesis would be fitter than the fittest 
homozygote and in the dominant theory, the heterozygote would be fitter that the 
homozygotes on average, but no more than the fittest homozygote. The negative 
frequency-dependent selection hypothesis, also known as the rare-allele advantage 
hypothesis, proposes that parasites evolve to exploit the defects in the most common host 
genotype, and the host therefore benefits from the rare alleles. Fluctuationg selection 
proposes that the spatial and temporal diversity and the amount of pathogens are the 
driving force, rather than co-evolution.  
The reproductive model is based on sexual selection and also has two different 
hypotheses. The first suggests that disease-based fitness differences between MHC 
genotypes favour reproductive mechanisms that would produce offspring with high fitness 
genotypes. This MHC-dependent mating might enhance parasite resistance in two ways, 
either by providing advantageous heterozygotes or by racing with the evolution of 
mutating parasites. The latter is known as the moving target hypothesis. The second 











MHC has been associated with almost every autoimmune disease, although the causal 
variants are not being characterized in most cases due to extensive linkage disequilibrium 
(LD) in the region 
54
. Some of the predisposing HLA alleles and haplotypes have been 
listed along with other susceptibility genes in Table 1. 
2.1.4. Environmental background of autoimmune diseases 
Autoimmune diseases have a strong genetic influence, but often environmental factors are 
needed to trigger the disease in genetically predisposed individuals. There are several 
mechanisms by which pathogens trigger the autoimmune diseases. Firstly, autoreactive T-
cells can be activated via molecular mimicry by cross-reactive recognition of an infectious 
antigen that has similarity to self-antigen. Secondly, infection causes tissue damage, 
revealing self-antigens that are normally not exposed. This together with the secreted 
inflammatory mediators may activate bystander lymphocytes not specific to the pathogen. 
Self-antigens can then be taken up by activated APCs, processed and presented to 
autoreactive T-cells in a process known as bystander activation. Tissue destruction may 
also cause epitope spreading. Thirdly, microbial superantigens may activate a large subset 
of T-cells, some of which are specific to self-antigens. In most cases, the autoimmune 
reaction ends as the pathogen is eradicated, but may sustain in genetically predisposed 
individuals. Drugs and toxins may react chemically with self-proteins and form 
compounds foreign to the immune system. These haptenated proteins may activate the 
immune response, leading to autoimmune reactions 
1
. It has also been suggested that 




The hygiene hypothesis proposes that the decreasing incidence of infections in 
developed countries is the cause of the increasing incidence of both autoimmune and 
allergic diseases. This cannot be explained only by different genetic background. For 
example, the incidence of type 1 diabetes (T1D) with the same genetic background is 
close to six-fold higher in Finland than in the adjacent Karelian Republic of Russia 
60
. On 
the other hand, environmental risk factors alone do not explain this difference, as 
evidenced by the high concordance of T1D in monozygotic twins. The best support for the 
theory is provided by different animal models, such as the non-obese diabetic (NOD) 
mouse 
61
. NOD mice bred in ‘conventional’ facilities show little or no diabetes, whereas 
close to 100% of the female NOD mice bred in specific pathogen-free conditions develop 
the disease. In addition, a protective effect of probiotics and bacterial extracts was 
reported at the onset of diabetes. The proposed underlying mechanism is a TH1–TH2 
deviation, caused by antigenic lymphocyte competition for cytokines, recognition for 
MHC-self-peptide and growth factors necessary for the activation of B- and T-cells. Also 
Treg cells or antigen-independent stimulation through TLRs may be involved. Two 
immune responses caused by different antigens are known to inhibit each other, and 
therefore, a strong immune response to a pathogen might inhibit a weak immune response 
to an autoantigen 
62
. 




2.1.5. Shared autoimmune disorders in humans and dogs 
The Online Mendelian Inheritance in Animal (OMIA) database lists a total of 506 
inherited diseases in dogs (20.09.2010), from which at least 235 are considered as 
potential disease models for human diseases. Table 1 lists the autoimmune diseases 
thought to be shared with humans and identified genes according to OMIA 
63
. Canine and 
human clinical diagnostics vary and dog diseases are usually not divided into as many 
sub-phenotypes as diseases in humans. Therefore, in the Table 1, human diseases are 






































































































































































































































































































































































































































































































































































































Epidemiological studies are scarce compared to human autoimmune diseases, but some 
dog breeds are clearly overrepresented with immunological disorders. Breed-specific 
prevalence estimates were reported only in 21 from a total of 312 disorders based on a 
PubMed search 
64
. The few examples available of prevalence estimates in autoimmune 
diseases are: haemolytic anemia 11-25% in eighteen different breeds, Sebaceous adenitis 
24% in Akitas. The Orthopedic Foundation for Animals lists breed statistics based on 
laboratory testing. These numbers are only indicative since the individuals may not 
present random sampling of a breed, although some numbers of evaluated animals are 
high enough to make suggestive conclusions. In Table 2 are listed some examples of the 
breeds predisposed to hypothyroidism. A recent study in Swedish Giant Schnauzers gave a 
prevalence of 16% for the canine autoimmune lymphocytic thyroiditis (CLT) as it is here 
6.6% 
65
. A similar phenotype in human is Hashimoto’s thyroiditis which has been listed as 
a rare disease by Orphanet, the portal for rare diseases and orphan drugs (www.orpha.net). 
 
Table 2 Top 25 breeds affected with hypothyroidism according to Orthopedic Foundation 
for Animals database. Breeds with over 50 evaluations are listed. Modified from www.offa.org, 
24.22.2010. 
 
2.1.5.1 Systemic lupus erythematosus (SLE) 
Lupus erythematosus (LE) in humans is a heterogeneous autoimmune disease with 
varying immune responses and clinical course. LE can be divided into two subclasses 







cutaneous lupus erythematosus (CLE). CLE can be subdivided to discoid lupus 
erythematosus (DLE), acute cutaneous lupus erythematosus and subacute cutaneous lupus 
erythematosus (SCLE), which usually manifest solely in skin lesions, but may sometimes 
show extracutaneous signs. SLE is a multisystemic disease with variable symptoms such 
as skin manifestations, arthritis, serositis, proteinuria and neurological disorders. 
Autoantibodies are infrequent in DLE, but are practically always present in SLE in 
multiple specifities and almost always in SCLE. One of these autoantibodies is antinuclear 
antibody (ANA) 
66,67
. The prevalence of SLE varies between different populations from 
3/100 000 in Iceland and Japan to 91/100 000 in Spain 
68
. The CLE prevalence has not 
been as widely studied, but is estimated to be two to three-fold more common than SLE 
69
. 
Both genetic and environmental factors are thought to contribute to the aetiology, and 
selected genes underlying SLE have been listed in Table 1. 
2.1.5.2 Hypoadrenocortisism (Addison’s disease, AD) 
The clinical and pathological features of Addison’s disease (AD) were first described by 
Thomas Addison in 1855. AD is caused by insufficient production of corticosteroids and 
mineralocorticoids due to autoimmune destruction of the adrenal cortex 
70
. Autoantibodies 
in AD are directed against the enzymes involved in steroid synthesis, and they have 
predictive use, which is exploited by the ACTH stimulation test, detecting subclinical 
adrenocortical dysfunction with a high sensitivity. Isolated AD cases are rare and usually 
accompanied by other endocrinopathies such as autoimmune thyroid disease, pernicious 
anaemia and diabetes mellitus. AD is a part of the autoimmune polyendocrine syndrome 
(APS) in 100% of APS II cases and in 72% of APS I (APECED) cases. The prevalence of 
APECED is increased in Finland and is included in the “Finnish heritage of disease” with 
a prevalence of 1/25 000 
71
 The prevalence of AD in the general population is from 30/1 
000 000 to 60/1 000 000 
72
. The aetiology of AD is not fully understood, but, as a part of 
the APS I, it has been associated with the HLA-DRB1*03 allele, whereas other symptoms 
of APS I are associated with over 60 different mutations in the AIRE gene and other MHC 
class II variants 
71
. AD in the isolated form and in the context of APS II has been 
associated with HLA-A1, -B8 and -DR3 
72
. 
2.1.5.3 Autoimmunity in the eye: an immune-privileged site 
Immune-mediated diseases are relatively common in humans and dogs and present 
mechanistically interesting autoimmune conditions without reactive lymphoid tissues. 
Ocular disorders may affect the eye globe as a whole or individual structures such as the 
cornea, conjunctiva and eye lids, sclera and episclera, optic neuron, retina and extraocular 
muscles 
73
 (Figure 3). This might seem surprising because of the absence of lymphatic 
drainage, except for the conjunctiva, and selective blood-ocular barriers, which restrict the 
access of antigens to potentially reactive lymphoid tissue. The cornea has for long even 








Autoimmune uveitis in humans comprises a group of potentially blinding ocular 
inflammatory diseases, with an annual incidence of over 150 000 persons in the United 
States. Anterior uveitis is less destructive to the vision and affects mainly the front of the 
lens. Posterior uveitis (uveoretinitis) is more likely to result in blindness due to 
irreversible damage to the neural retina and adjacent structures. Posterior uveitis may 
involve only the eye, as in sympathetic ophthalmia and birdshot retinochoroidopathy or be 
a part of a systemic syndrome, such as of Behcet’s disease, sarcoidosis and Vogt-






Figure 3 Ocular immune-mediated diseases in dogs. Many of these diseases are poorly 
described and the pathogenesis is mostly unknown. 
2.1.6 Autoimmune disorders in Nova Scotia Duck Tolling Retrievers 
Nova Scotia Duck Tolling Retrievers (NSDTRs) are highly susceptible to several 
autoimmune diseases, including IMRD, SRMA and AD. Other autoimmune diseases, such 
as AIHA and hypothyroidism, have been reported in lower frequency by the Finnish breed 
club. IRMD and SRMA may be a part of the same immune disease syndrome SLE-related 
disease 
15,17,18
. We focused on IMRD, SRMA and AD, which will be described in more 
detail below. 
2.1.6.1 SLE-related disease  
IMRD and SRMA are hypothesized to be a part of the same autoimmune disorder, SLE-
related disease syndrome, based on the breed predisposition and segregation of both 









2.1.6.1.1 Immune mediated rheumatic disease (IMRD) 
Typical immune-mediated rheumatic disease (IMRD) -affected dogs show similar clinical 
signs as patients with human SCLE and SLE; 84% of SCLE patients and 96% of SLE 
patients show antinuclear antibodies, while IMRD-affected dogs show ANA positivity in 
70% of cases. Another typical clinical sign is polyarthritis, which is seen in 16% of SCLE 
and 68% of SLE patients, whereas all IMRD dogs display arthritis. Other common 
symptoms include skin manifestations, fever and kidney and liver problems 
15,76,77
. The 
median age of disease onset is three years, and the disease frequency is clearly elevated 
compared with other breeds 
15
. The prevalence of SLE has not been studied in dogs, but it 
is a rare disease in dogs in general. In eleven-year period (1991-2001), 83 dogs had been 
diagnosed with noninfectious, nonerosive, immune-mediated polyarthritis, from which 
only seventeen dogs had been confirmed to have SLE, in the veterinary teaching hospital 
at the Western College of Veterinary Medicine. The total number of canine patients from 
this period was 23 661 
78
. In a five-year period (2002-2007), 121 SLE affected dogs had 
been tested ANA positive in Clinical Pathology Laboratory of the University Animal 
Hospital in Uppsala and 26% of these dogs were NSDTRs, suggesting that this breed is 
highly susceptible for IMRD.  
2.1.6.1.2 Steroid-responsive meningitis arteritis (SRMA) 
Dogs have two forms of steroid-responsive meningitis arteritis (SRMA). In the acute form 
of SRMA, acute neck pain is typical, which manifests in a reluctance to turn the head and 
lowering it while walking. Other clinical signs are fever, stiff gait, hunched back while 
walking, depression and anorexia, probably because of difficulties in lowering the head 
and opening the mouth. Often dogs pant excessively due to severe pain. Cerebrospinal 
fluid (CFS) shows a significant neutrophilic pleocytosis and an elevated protein 
concentration. CSF is not a widely used diagnostic method, and therefore, exclusion of the 
main potential differential diagnoses, such as disc herniation and polyarthritis of the 
cervical facet joints, as well as breed disposition, are used to confirm the diagnosis. The 
more protracted form shows severe neurological signs such as ataxia, paresis, tetraparesis 
or paraplegia, mild to moderate mixed cell pleocytosis in CSF and possible protein 
elevation. Some dogs develop polyarthritis, which is always seen in IMRD-affected dogs. 
The dogs develop signs of SRMA at the age of 4-19 months and a lifelong therapy with 
corticosteroids may be needed to avoid relapses, which occur in 50% of cases. 
Unresponsiveness to medical treatment may lead to euthanasia. The estimated prevalence 
of SRMA according to a Norwegian study is around 2.5%, which may be underestimated 
because of strict inclusion criteria 
17
. 
2.1.6.2 Hypoadrenocortisism (Addison’s disease, AD) 
Dogs as well as humans affected with AD often present with a variety of non-specific 
signs, including vomiting, diarrhea, lethargy, anorexia, muscular weakness and depression 
79-81
. The age of onset in NSDTRs is around four years, and the dogs as well as humans 




are treated by supplementing the missing hormones 
80
. The diagnosis is confirmed with an 
ACTH stimulation test. 
2.1.7 Autoimmune disorders in German Shepherd dogs 
From all breeds, German Shepherd dogs have been reported to have the most inherited 
defects, total of 77 
64
. Even if conformation-related defects are excluded, the number of 
familial disorders is 58. It is therefore not surprising that also several autoimmune diseases 
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26
. Our focus in this study is on CSK, 
which will be described here in more detail. 
2.1.7.1 Canine chronic superficial keratitis (CSK) 
Canine chronic superficial keratitis (CSK) is a progressive autoimmune ocular disease 
often leading to blindness if left untreated. Characteristic for CSK is progressive, bilateral 
vascularisation, fibrous tissue formation and pigmentation of the anterior corneal stroma 
20
 






Figure 4 Progressive, bilateral vascularization, fibrosis and pigmentation of the 
anterior corneal stroma in the eye of German Shepherd Dog affected with chronic 
















Table 3 Dog breeds reported with chronic superficial keratitis in the literature.  
 
The initial phase of CSK mainly involves IFN-  -producing CD4+ T-lymphocytes that 
infiltrate from the temporal region of the limbus into the superficial corneal stroma. The 
next phase involves invading macrophages, plasma cells and neutrophils 
87
. Increased 
expression of MHC class II proteins has been observed in the central cornea. This aberrant 
MHC class II expression has been proposed to be associated with the IFN-  secretion of 
the invading T-helper cells 
41
. The presence of CD4+ T-cells is typical for ocular 
autoimmune diseases 
88
. In addition, CSK is responsive to topical steroids and 
cyclosporine, further indicating an autoimmune origin 
89
. 
2.2. The dog as a model species for human inherited disorders 
2.2.1 Origin of the domestic dog 
Dogs were domesticated from wolves less than 16 300 years ago 
90
 (Figure 5). The latest 
study based on genomes of mitochondrial DNA (mtDNA) suggest that the existing canine 
breeds have a common origin, most probably in south-eastern Asia, south of the Yangtze 
river. It is estimated that at least 51 female wolves with different mtDNA haplotypes and a 
total of several hundred individuals were domesticated and that the modern domestic dogs 
originate from these wolves 
90
. Domestication has been estimated to have a 5% reduction 
in nucleotide diversity, whereas breed formation resulted in an average reduction of 35% 
91
. Therefore, the domestication event itself has not affected the genetic diversity as 
extensively as modern breeding practices.  





Figure 5 Illustration of the bottlenecks in the history of the domestic dog. 
2.2.2 Breed creation 
Most of the over 400 modern dog breeds have been created over the last 400 years. The 
founder effect is very strong in pure-bred dogs 
4
. Each pure breed represents a group of 
genetically very similar animals that have descended from only a few ancestors. Some 
breeds have gone through several severe bottlenecks during the World Wars or depression 
and infectious disease breakouts, reducing the effective breeding population to only a few 
dogs. Modern breeding practices have also extensively narrowed the genetic diversity. 
Tight inbreeding accumulates recessive disease alleles and the frequency of these alleles is 
further increased by a use of ‘‘popular sires’’. Popular sires are dogs successful in dog 
shows or in competition events or otherwise considered superior representatives of the 
breed, and they may produce >100 litters in their lifetime.  
It is clear that in-breeding accumulates recessive mendelian diseases, but the effect of 
‘in-breeding depression’ on polygenic, late-onset diseases is more complex. Firstly, the 
combined effect of individual risk factors for complex disease is multiplicative rather than 
additive. Secondly, late-onset diseases may not be selected against as they are first visible 
after reproductive age. Thirdly, the negative effects of rare homozygous mutations may be 
more severe than effects of common risk variants, as they usually do not exist in out-bred 
populations where homozygotes are rare. Fourthly, in-breeding affects the response to 







exists, inbreeding reduces clearly the polymorphism and even if homozygosity itself is not 
harmful in some genes or gene areas, these benefits are lost 
92
. As an example of 
inbreeding effects, the study of sea lions in California showed increased bacterial and 
helminth infections and longer recovery time 
93
. 
As a result of the founder effect and tight inbreeding, breed-specific physical features, 
behaviour and over 500 diseases, such as epilepsies, cancers, allergies and autoimmune 
disorders, have been accumulated in pure-bred dogs 
4
. Only humans have been identified 
with more known genetic diseases. Today the OMIA database identifies 506 inherited 
canine diseases and more than 60% of these are thought to be shared with humans with 
very similar physiology, disease presentation and clinical response. Even among the top 
ten most common inherited canine diseases, there are several that serve as a disease model 
for humans 
3-5
. Mutations behind several monogenic diseases have already been identified, 
such as the hair ridge, which causes predisposition to dermoid sinus 
12
, recessive cone-rod 
dystrophy 
13
 and ectodermal dysplasia 
14
. 
2.1.2.1 Nova Scotia Duck Tolling Retriever 
The NSDTR was developed in the Yarmouth region of Nova Scotia in 
the early 1800s as a gundog to assist hunters to lure and retrieve 
ducks. Canine Distemper Virus (CDV) outbreaks were reported to 
occur twice in 1908 and 1912 reducing the population to only a few 
individuals. The first NSDTRs registered with the Canadian Kennel 
Club (1945) were derived from the stock that survived these distemper 
outbreaks, and the first NSDTRs were imported to the Scandinavian 
countries as late as in the middle of the 1980s 
94
 (Figure 6). 
Figure 6 Novascotian Duck Tolling Retriever. Photo Jarno 
Nevalainen. 
2.2.2.2 German Shepherd Dog 
The GSDs originate from the herding and farm dogs in southern- and 
central Germany and have been systematically bred since the breed 
club ”Verein für Deutche Schäferhunde” was founded in 1899. The 
purpose was to create a versatile working dog to serve humans and 
the breed remains the most popular working dog worldwide. The first 
GSDs were imported to Finland in the 1910s 
95,96
 (Figure 7). 
Figure 7 German Shepherd Dog. Photo Eila Kärkkäinen. 




2.2.3 Dog genome and genomic tools 
The fundamental element in identifying the genes for a particular characteristic or disease 
is a founder effect. The study cohort would ideally consist of individuals with a common 
ancestry such as Icelanders and Finns in humans, and inbred laboratory animals or pure-
bred breeds of pet dogs. When the population descends from a small group of ancestors, 
they are more likely to share the same founder mutations, and genetic heterogeneity is 
much lower. In a study of 85 dog breeds, humans and dogs were shown to have essentially 
the same level of nucleotide heterozygosity when all the dog breeds were considered as 
one species. As stated earlier, the genetic diversity did not markedly diminish during 
domestication of the dog from wolves. Within a dog breed, the homogeneity is much 
greater than within distinct human populations, 94.6 % and 72.5%, respectively, which is 
supported by the history of severe bottlenecks in breed creation. Therefore, much of the 
total genetic variation comes from differences between dog breeds and is nearly 6-fold the 
variation between human populations 
97
. 
2.2.3.1 Dog genome structure provides advantages in gene mapping 
The dog genome consists of 76 acrocentric autosomes, and two sex chromosomes. A 
female chromosome is X and a male chromosome Y, giving a total diploid number of 78. 
The abbreviation CFA is used here for canis familiaris chromosomes. The dog genome 
project, which was completed in 2005, provided a high-quality dog genome sequence and 
a dense single-nucleotide polymorphism (SNP) map containing 2.5 million SNPs. In 
addition, a detailed haplotype analysis was performed on the whole boxer sequence and a 
6% sequence of the genome from 10 additional dogs representing different breeds 
9
. LD in 
domestic dog breeds correlates with breed history. Breeds like the akita, Bernese mountain 
dog and Pekingese, which have experienced severe bottlenecks in the last 100 years, have 
LD blocks that extent over 3 Mb. In golden and Labrador retrievers, which are popular 
breeds without severe bottlenecks in the past, the LD blocks are around 1 Mb. By 
comparison, in humans, LD blocks are < 100 kb. Extensive LD blocks are an advantage in 
genome-wide association studies where fewer markers are needed to map the genomic 
location of the association. The disadvantage is that the identified loci are usually several 
megabases long. Strong inbreeding of dogs has also resulted in low haplotype diversity in 
regions of extensive LD, and dog breeds, although highly differentiated genetically, share 
haplotypes with each other to a high degree. Shared haplotypes are short (<10 kb) and 
enable the use of related breeds with the same phenotype, and presumably with the same 








Figure 8 Haplotype surrounding the mutation in ancestral wolf haplotype and in 
haplotypes on chromosomes of modern dog breeds. 
Power calculations estimate that genome-wide association analyses may be performed 
on dogs with 15 000 SNPs. To identify alleles for a simple recessive trait, 20 affected and 
20 healthy control dogs are needed. To map complex traits, one would need at least 100 
cases and 100 controls for traits that have a fivefold increased risk. For complex traits with 
only a twofold increased risk, 500 cases and controls are estimated to be needed 
9
.  
There are several other reasons why the dog is an excellent model for complex 
diseases, in which both genes and environmental risk factors contribute to the 
development of the disease. Dogs share most of the environmental risk factors with 
humans. As companion animals, dogs are exposed to smoking, environmental pollution, 
toxins, radon and sometimes even the same diet. The health of companion dogs is well 
taken care of and documented. The insurance companies and breed and kennel clubs keep 
records of pedigrees, and diseases and there are several databases and computing tools 
available for genetic research. Also full post-mortem tissues are available. Most 
importantly, the coding sequences of dogs and humans are more similar to each other than 
to mice and they have a similar physiology, histology and clinical course of the disease 
6,98
. 
2.2.3.2 Dog genetic resources and genomic tools available 
New high-throughput technology and dog genome sequence, enable studies at a genome-
wide level within a reasonable time and relatively low costs. The dog genome sequence 
and related resources are available in the databases of the University of California, Santa 
Cruz (UCSC) http://genome.ucsc.edu/ and the National Center for Biotechnology 
Information (NCBI) http://www.ncbi.nlm.nih.gov/projects/genome/guide/dog/. Moreover, 
several databases on canine inherited disorders are available, including the Online 
Mendelian Inheritance in Animals (OMIA) database at the NCBI site 
http://omia.angis.org.au/, Canine Inherited Disorders Database (CIDD) 




http://www.upei.ca/cidd/intro.htm, which is a joint initiative  of the Sir James Dunn 
Animal Welfare Centre at the Atlantic Veterinary College, University of Prince Edward 
Island, and the Canadian Veterinary Medical Association and the Inherited Diseases in 
Dogs Database (IDID) http://server.vet.cam.ac.uk/index.html compiled by David Sargan 
at the University of Cambridge. In addition, there are several web pages related to genetic 
research, including the FHCRC Dog Genome Project at the National Human Genome 
Research Institute, which is a part of the National Institutes of Health (NIH) in Bethesda, 
Maryland, the Animal Healthtrust in Newmarket, Suffolk http://www.aht.org.uk/ and the 
LUPA project, a collaborative research project funded by the European commission under 
the 7th research framework programme http://www.eurolupa.org/. 
Traditional sequencing and microsatellite markers are still used, but the new SNP-, 
CNV- and sequencing array technologies have revolutionized genetic research. The first 
genome-wide SNP genotyping microarray generated by collaboration of the Broad 
Institute and Affymetrix contained ~27 000 markers. The improved version with ~50 000 









3 Aims of the study 
The purpose of this study was to identify genetic loci and variants influencing the 
susceptibility to different autoimmune diseases in dogs. The main approaches used in this 
thesis were demonstrating association through known MHC class genes and 
demonstrating SNP association through a genome-wide association study.  
 
Specific aims were as follows:   
 
1. To investigate whether MHC class II genes DRB1, DQA1 and DQB1 are associated  
a. with IMRD , SRMA and Addisons’ disease in NSDTRs.  
b. with CSK in GSDs. 
2. To identify novel susceptibility loci for IMRD, SRMA and Addisons’ disease in 
NSDTRs by a genome-wide association study. 




4 Materials and methods 
4.1 Research site 
This study was carried out in Professor Hannes Lohi’s research group at the Department 
of Veterinary Biosciences, the Department of Medical Genetics, the Program in Molecular 
Medicine, University of Helsinki, and The Folkhälsan Institute of Genetics, Department of 
Molecular Genetics, Biomedicum I, Helsinki. 
SLE project was conducted in collaboration with the research groups of Professor 
Kerstin Lindblad-Toh at the Broad Institute of Harvard and Massachusetts Institute of 
Technology (MIT), USA, and the Department of Medical Biochemistry and Microbiology, 
Uppsala University, Sweden, Associate Professor Helene Hansson-Hamlin at the 
Department of Clinical Sciences, Swedish University of Agricultural Sciences (SLU) and 
Professor Göran Andersson at the Department of Animal Breeding and Genetics, SLU. 
The Addison’s disease project was conducted in collaboration with Associate Professor 
Danika Bannasch at the Department of Population Health and Reproduction and Angela 
Hughes, DVM at the Department of Medicine and Epidemiology, University of 
California, USA. Lorna Kennedy, PhD of the University of Manchester has assisted with 
MHC haplotyping in all three MHC studies. 
4.2 Study population 
A total of 222 NSDTRs, 65 GSDs, six Cocker Spaniels, twelve boxers and four Petit 
Basset Griffon Vendeens were included as cases in our studies. In addition, 203 NSDTRs, 
39 GSDs, four Cocker Spaniels, twenty boxers and six Petit Basset Griffon Vendeens 
served as healthy controls. The case control association analysis was performed with 44 
SRMA dogs, 37 IMRD and 57 controls. Table 4 describes the study population in detail. 
Affected dogs and population controls, unrelated at the grandparent level, were used in 
all studies, except the AD study, where we used discordant sib-pairs. A partial pedigree of 



































































































































































































































































































































































































































































































































































































































































































































































































































4.3 Diagnostic procedures 
Dogs were chosen based on strict inclusion and exclusion criteria. To be classified as 
affected by IMRD, the dogs had to have displayed musculoskeletal disorders consistent 
with symmetrical polyarthritis, suffered from pain affecting several joints of the 
extremities and displayed stiffness, mainly after rest. Signs needed to be apparent for at 
least 14 days. The presence of ANA was tested by using indirect immunofluorescence 
(IIF-ANA).  The test was considered positive at a titre of 1:100. 33 out of 51 study dogs 
tested IIF-ANA positive. Positive ANA tests were repeated 2-3 months later, with the 
same positive result and the same IIF-ANA pattern. Sera from all healthy controls were 
negative on the IIF-ANA test. Dogs classified as SRMA-affected displayed high fever and 
strong neck pain and responded to corticosteroid treatment. The diagnostics procedure is 
described in more detail by Hansson-Hamlin 
15
. 
For a dog to be classified as affected by AD, an adrenocorticotropic hormone (ACTH) 
stimulation test must have been performed with pre- and post-ACTH stimulation serum 
cortisol concentrations <2.5 g/dl (68 nmol/l). Exclusion criteria were dogs with no 
clinical signs of any autoimmune disease and >7 years of age.  
The dogs diagnosed with CSK, as well as the healthy controls, had undergone a 
thorough ophthalmic eye examination by an experienced ophthalmologist to ensure their 
recent ocular health status. We also developed a detailed health questionnaire that was sent 
to all participating dog owners. Besides the demographic information and specific 
questions about CSK, the questionnaire collected information about the dog’s relatives. 
All dogs affected with any other eye or autoimmune diseases were excluded. 
4.4 Blood samples and DNA isolation 
All animals in our study were privately owned pets. A DNA sample was donated for use 
in a genetic study. EDTA- blood (3-5 ml) was collected at various veterinary clinics and 
dog shows with the owners’ consent. DNA was isolated using standard procedures 
(studies II, III). 
4.5 Sequencing for MHC class II and allele assignment (I-III) 
To identify the MHC class II haplotypes, we first sequenced the purified PCR products of 
exon 2 from DLA locus genes DRB1, DQA1 and DQB1 using an ABI 3730 or 3730xl 
sequencer. The sequences were analysed manually and compared with a consensus 
sequence with the MatchToolsNavigator program. The program MatchTools was used to 
assign the DRB1-, DQA1- and DQB1 alleles by comparing the sequences against a large 
sequence library (http://www.ebi.ac.uk/ipd/mhc/index.html). MHC-II haplotypes were 
built using information from previous studies (Dr. Lorna Kennedy, personal data). 




4.6 Genome-wide genotyping (IV) 
Genome-wide association (GWA) genotyping was performed at Biomedicum Helsinki 
using 22,000 validated SNPs in the CanineSNP20 BeadChip panel and the Illumina’s 
Infinium HD DNA Analysis instrument. Automated genotype calling was performed using 
the Illuminus software 
99
.  
4.7 Fine-mapping of the associated regions (IV) 
A total of 822 SNPs at 1 SNP/10 kb density were genotyped by the iPLEX SEQUENOM 
MassARRAY platform at the Broad Institute. Fine-mapping was performed with samples 
used in GWA, additional samples of NSDTRs and dogs with the same phenotype from 
other breeds. Additional breeds with the IMRD or SRMA phenotype were included to 
identify shared haplotypes across breeds (Figure 8).  Also NSDTRs with other 
autoimmune diseases, AD and CLT, were included to identify loci predisposing to 
autoimmune disorders in general. The total sample size at this point was 416 NSDTRs and 
included 81 IMRD cases (32 ANA-positive), 78 SRMA cases, 43 AD cases, 20 CLT cases 
and 203 healthy controls. The details of the samples are presented in Table 4. The normal 
procedure requires an independent association in each breed, but due to low sample sizes 
we performed the haplotype analysis without this prior knowledge. 
4.8 Statistical analysis (I-IV) 
In studies I-III, the cases and controls were divided into separate groups in various ways 
based on the presence or absence of an allele, genotype or haplotype. In each group the 
number of allele, genotype or haplotype was calculated and a 2x2 Contingency Table was 
created to display the proposition of each variable in a matrix format. The significance of 
the frequencies between cases and controls was assessed by 
2
 statistics and odds ratios 
(OR) and relative risks with 95% or 99% confidence intervals and p-values were 
calculated. While calculating the OR for the risk haplotype homozygosity in CSK and AD 
where the number of homozygous controls was zero, we used a pseudocount (1) to be able 
to perform the calculations. This approach means adding number one to each observed 
number of counts 
100
. 
In study IV, all SNP and haplotype associations were analyzed with the software 
package PLINK 
101
. For marker quality control, SNPs with a minor allele frequency of 
<5% were excluded, as were SNPs with call rates <75%. Our GWA samples were 
collected from two different countries in which the NSDTR breed may have been divided 
into separate subpopulations causing a false association due to differentiated allele 
frequencies between the subpopulations (=population stratification, PS). To test for the 
presence of PS in our sample we used multidimensional scaling (MDS) analysis to 
construct multidimensional scaling plots, where each spot corresponds to a specific 
individual. PS was adjusted by IBS clustering with two groups, which reflects the 







and chose Cochran-Mantel-Haenszel (CMH) conditional on clustering as the primary 
association analysis method 
102
. The robust and generally accepted p<5 x 10-6 was chosen 
as the limit for significance, with further interest for follow-up studies paid to loci 
showing with multiple SNPs within close proximity with p-values between 1 x 10-5 - 5 x 
10-6. A quantile-quantile plot of the CMH analysis and overall inflation factor (  = 1.2) 
were used as final quality control measures. The genome-wide significance was assured 
by using 100 000 permutations. The analysis was performed for the IMRD and SRMA 
sub-phenotypes separately and all cases combined. 
At fine-mapping stage, for marker quality control, SNPs with a minor allele frequency 
of <1% were excluded, as were SNPs with call rates <80%. The same settings were used 
to analyse two to eight SNP haplotypes generated with a sliding window approach 
provided by PLINK. 
4.9 Ethical issues 
We have a license authorized by the Animal Experiment Committee of the County 
Administrative Board of Southern Finland (ESLH-2009-07827/Ym-23, valid until 
16.10.2012). No genetically modified dogs are produced in our Finnish dog genetics 
programme. We do not breed dogs for research purposes or own any of the dogs studied. 





5.1 MHC class II candidate gene studies (I-III) 
MHC class II gene region has been associated in most, if not all, autoimmune disorders in 
humans and in several autoimmune disorders in dogs. As there are no previous genetic 
studies reported in CSK, IMRD, SRMA or AD, we investigated whether specific DLA-
DRB1*DQA1*DQB1 – risk haplotypes exist in any of these disorders. 
5.1.1 DLA class II polymorphism in Finnish, Swedish and North-American 
NSDTRs 
We genotyped altogether 241 NSDTRs, 64 from Finland, 114 from Sweden and 63 from 
North America (Table 4) and identified five DLA-DRB, four DLA-DQA1 and five DLA-
DQB1 alleles, which formed seven different haplotypes (Table 5). Two of the most 
common haplotypes were seen in very high frequencies, the third, fourth and fifth most 
common haplotypes were seen in moderate frequencies and the rest were extremely rare, 
seen in only a few dogs. A clear difference existed in haplotype one and five frequencies 







Finnish and Swedish dogs showed a similar distribution of haplotypes with 
each other, as did the US and Canadian dogs. 
Table 5 Haplotype frequencies in Scandinavian and North-American Nova Scotia Duck 
Tolling Retrievers. 
Haplotype 
no. DRB1 Allele DQA1 Allele DQB1 Allele
1 00601 005011 02001 142 40.3 31 22.8
2 01502 00601 02301 120 34.1 43 31.6
3 01501 00601 00301 53 15.1 26 19.1
4 02301 00301 00501 34 9.7 10 7.4
5 01501 00601 02301 22 16.2
6 00401 00201 01501 3 0.9 2 1.5
7 01502 00601 00301 2 1.5
Total 5 4 5 352 100.0 136 100.0
Scandinavian AmericanHaplotype
Haplotype frequency       
(no.    +    %)
Haplotype frequency       
(no.    +    %)
 
5.1.2 DLA class II polymorphism in Finnish GSDs 
We genotyped 55 GSDs and identified eight DLA-DRB1, five DLA-DQA1 and eight 
DLA-DQB1 alleles, which formed eleven different haplotypes (Table 6). The haplotypes 
were unevenly distributed and the two most common ones were seen in very high 
frequencies, comprising over 75% of all haplotypes in the study population. A third 







rare, seen only in one to three dogs. Three of the dogs carried a double DLA-DQB1 allele 
on one haplotype, consisting of alleles DQB1*01303 and DQB1*01701; this was named 
DLA-DQB1*013017. One of the identified alleles in the DLA-DRB1 locus was new and 
was officially named DLA-DRB1*01104 and submitted to the NCBI database (accession 
number FN995992). One DLA-DQB1 allele was also new and has now officially been 
named DLA-DQB1*05901 (accession number FN995993). 
Table 6 Haplotype frequencies in the Finnish German Shepherd Dogs. 
Haplo-type 
no. DRB1 Allele DQA1 Allele DQB1 Allele
1 01101 00201 01302 20 34.4 26 53.3 46 41.8
2 01501 00601 00301 26 43.1 11 22.2 37 33.6
3 00101 00101 00201 5 8.6 5 11.1 10 9.09
4 00201 00901 00101 1 1.7 2 2.2 3 2.7
5 00102 00101 00201 2 3.4 1 0 3 2.7
6 01201 00401 013017 1 1.7 2 4.4 3 2.7
7 01502 00601 02301 2 3.4 2 1.8
8 01104 00201 01302 2 4.4 2 1.8
9 01502 00601 05901 2 3.4 2 1.8
10 01101 00201 01303 1 1.7 1 0.9
11 01501 00601 02301 1 2.2 1 0.9
Total 8 5 8 60 100 50 100 110 100
Haplotype frequency    
(no.    +    %)
All
Haplotype frequency    
(no.    +    %)
Haplotype frequency    
(no.    +    %)
CSK ControlsHaplotype
 
CSK=chronic superficial keratitis 
5.1.3 DLA class II haplotype association with CSK in GSDs 
We genotyped thirty affected CSK dogs and twenty-five healthy population controls to 
search for an association with the MHC class II region. All of the dogs participating in the 
study had been examined by an experienced ophthalmologist to confirm the diagnosis, to 
exclude other eye diseases and to confirm the recent health status of control dogs. The 
DLA-DRB1*01501/DQA1*00601/DQB1*00301 haplotype was significantly associated 
with the CSK in GSDs (OR=2.67, 95% CI=1.17-6.44, p = 0.02) (Table 7). 
Table 7 Association of the risk haplotype DRB1*01501/DQA1*00601/DQB1*00301with 
chronic superficial keratitis in German Shepherd Dogs. 
CSK % (no.) Control  % (no.) Odds ratio 95% CI p-value
43.1 (26) 22.2 (11) 2.67 1.17-6.44 0.02
DRB1*01501/DQA1*00601/DQB1*00301
Association with risk haplotype
 
CSK=chronic superficial keratitis 
 




5.1.4 DLA class II haplotype association with hypoadrenocortisism in 
NSDTRs 
To test for an association between the MHC class II locus and AD, we genotyped twenty-
nine AD-affected NSDTRs, twenty-one from the USA and eight from Canada. The 
diagnosis was based on the ACTH stimulation test. In addition, five AD-suspected 
NSDTRs were included, three from the US and two from Canada. The diagnosis of these 
dogs was based on clinical signs and findings, and response to treatment.  Eleven 
unaffected full- and half-siblings of the affected NSDTRs, nine from the US and two from 
Canada, and twenty-three country-matched NSDTRs were included as controls. We found 
that the DLA-DRB1*01502/DQA*00601/DQB1*02301 haplotype was significantly 
associated with AD in NSDTRs (OR = 2.1, 95% CI = 1.0-4.4, p = 0.044) (Table 8). The 
association was even stronger when examining the US population alone (OR = 2.8, 95% 
CI = 1.1-7.1, p = 0.025). 
Table 8 Association of the risk haplotype DLA-DRB1*01502/DQA*00601/DQB1*02301 
with hypoadrenocortisism in American Nova Scotian Duck Tolling Retrievers. 
Addison's disease          
% (no) Control  % (no.) Odds Ratio 95% CI p-value
USA dogs 39.6 (24) 18.8 (24) 2.8 1.1-7.1 0.044
Canadian dogs 40.0 (10) 35.0 (10)
All dogs 38.6 (34) 22.9 (34) 2.1 1.0-4.3 0.047
DLA-DRB1*01502/DQA*00601/DQB1*02301
Association with risk haplotype
 
5.1.5 DLA class II haplotype association with IMRD in NSDTRs 
A total of 176 dogs were genotyped in this project. We studied 51 IMRD dogs, 33 dogs of 
which tested ANA positive on the IIF-ANA test. The sample also included 49 SRMA dogs 
and 78 healthy controls. Two dogs were affected by both SRMA and IMRD. We found an 
elevated risk for IMRD in dogs that carried the DLA-
DRB1*00601/DQA1*005011/DQB1*02001 haplotype (OR = 2.0, 99% CI = 1.03-3.95, p 
= 0.01) and for ANA-positive IMRD dogs (OR = 2.3, 99% CI = 1.07-5.04, p = 0.007) 

















Table 9 Association of the risk haplotype  DLA-DRB1*00601 /DQA1*005011 





51.0 (52) 34.6 (53) 2.0 1.0-4.0 0.01
ANA +
54.5 (33) 34.0 (53) 2.3 1.1-5.0 0.007
Association with risk haplotype
DLA-DRB1*00601 /DQA1*005011 /DQB1*02001
Control  % (no.) Odds ratio p-value 99% CI
 
IMRD=immune-mediated rheumatic disease, ANA=antinuclear antibody. 
5.1.6 Association of MHC class II homozygosity with autoimmunity 
Homozygosity for the risk haplotype increased the disease risk significantly in all studies. 
In CSK and AD, none of the control dogs were homozygous for the risk haplotype, 
whereas in IMRD 11.5% of the controls carried two copies of the risk haplotype. The 
DLA-DRB1*01501/DQA1*00601/DQB1*00301 haplotype was homozygous in 8 CSK-
affected dogs and none of the controls (ORestimate  > 8.5, 95% CI = 1.4-224, pfisher = 0.017) 
(Table 10). 
Table 10 Association of homozygosity in DRB1*01501/DQA1*00601/DQB1*00301 risk 
haplotype with chronic superficial keratitis in Finnish German Shepherd Dogs. Pseudocount (1) 
has been added to the numbers. 
CSK % (no.) Control  % (no.) Odds ratio 95% CI p-value
36.0 (9) 4 (1) 8.5 1.4-224 0.017
Homozygosity for risk haplotype
DRB1*01501/DQA1*00601/DQB1*00301
 
CSK=chronic superficial keratitis 
 
 
The DLA-DRB1*01502/DQA*00601/DQB1*02301 haplotype was homozygous in six 
AD-affected NSDTRs and in none of the controls (ORestimate  > 8.9, 95% CI = 1.4-237.7, 
pfisher = 0.02) (Table 11). 
Table 11 Association of homozygosity in the DLA-DRB1*01502/DQA*00601/DQB1*02301 
risk haplotype with hypoadrenocortisism in American Nova Scotian Duck Tolling Retrievers. 
Pseudocount (1) has been added to the numbers. 
Addison's disease         
% (no.) Control  % (no.) Odds ratio 95% CI p-value
20.6 (7) 3.5 (1) 8.9 1.4-237.7 0.02








The twofold risk present in heterozygous IMRD dogs increased up to fivefold if the 
dogs were homozygous for the haplotype (OR = 4.9, 99% CI = 1.52-16.0, p = 0.0005). 
ANA-positive dogs were even more susceptible, with a sevenfold risk (OR = 7.2, 99% CI 
= 2.0-25.9, p  0.0001) (Table 12). 
Table 12 Association of homozygosity in the risk haplotype  DLA-
DRB1*00601/DQA1*005011 /DQB1*0200 haplotype with immune-mediated rheumatic disease in 




39.2 (20) 11.5 (9) 4.9 1.52-16.0 0.0005
ANA +
48.5 (16) 11.5 (9) 7.2 2.0-25.9 <0.0001
Controls % (no.) Odds ratio p-value 99% CI
DLA-DRB1*00601 /DQA1*005011 /DQB1*02001
Homozygosity for risk haplotype
 
IMRD=immune-mediated rheumatic disease, ANA=antinuclear antibody. 
 
In addition, in CSK and AD, an overall homozygosity, regardless of the haplotype was 
shown to increase the risk, and in AD it was also associated with early onset of the 
disease. Fourteen out of 30 CSK cases versus four out of 25 controls were homozygous 
for the MHC class II haplotypes in general (OR=4.37, 95% CI=1.27-18.46, p = 0.02) 
(Figure 10). Ten AD-affected dogs were homozygous for MHC class II compared with 
only two control dogs (OR = 6.7, 95% CI = 1.5-29.3, p = 0.011) (Figure 11). 
 
Figure 10 Number of dogs homozygous for major histocompatibility complex (MHC) 
class II region: comparison of dogs with and without chronic superficial keratitis 








Figure 11 Number of dogs homozygous for the major histocompatibility complex (MHC) 
class II region: Comparison of dogs with and without Addison’s disease (AD). AD 
dogs indicated in dark grey and control dogs in light gray. 
5.2 Genome-wide association and fine-mapping studies in dogs 
(IV) 
In study IV, we performed the first successful genome-wide association study for a 
complex disease in dogs identifying IMRD and SRMA loci in NSDTRs . Genotyping on 
81 SLE-related disease affected dogs and 57 healthy control dogs was performed using the 
Illumina’s canine-specific 22k SNP chip arrays. GWA was followed by fine-mapping the 
associated regions with additional samples and markers. 
5.2.1 GWAS 
Based on the MDS analysis, we observed some stratification when all dogs were analysed 
together and when SRMA-affected dogs were analysed alone (Figure 12).  
 























Figure 12 Multidimensional scaling plot of the genome-wide SNP data showing minor 
population stratification (PS). When spots are totally overlapping each other, there is 
no PS. 
We identified five loci associated with the SLE–related disease complex, from which 
three loci reached genome–wide significance after correction for multiple tests (p-value = 
0.02-0.04). All results are combined in Table 13.  
We found a large region containing multiple associated SNPs on canine chromosome 
(CFA) 32 at 25 Mb (praw= 1.5 x 10
-5
 and pgenome= 0.12) when all cases were analysed as 
one group. After correction for stratification, the region showed an even stronger 
association (praw= 7.9 x 10
-6
 and pgenome= 0.06). 
Analysis of the ANA-positive IMRD sub-phenotype separately revealed four highly 
associated regions in CFA 3, 8, 11 and 24. The strongest associations were found for a 
single SNP on CFA 8 at 69 Mb (praw= 1.5 x 10
-6
 and pgenome= 0.02) and on multiple SNPs 
on CFA 24 at 38 Mb (praw= 3.2 x 10
-6
 and pgenome= 0.04). Both associations reached 
genome-wide significance. We also found multiple associated SNPs on CFA 11 at 66 Mb 
(praw= 7.4 x 10
-6
 and pgenome= 0.08) and on CFA 3 at 57 Mb (praw= 2.2 x10
-5
 pgenome= 
0.18), which did not reach genome-wide significance. Very minor population stratification 
(IR= 1.2) did not need to be corrected for. 
SRMA-affected dogs showed stronger stratification by nationality and were analysed 
in three different ways, as one group and as Swedish and Finnish dogs separately. When 
analysing all SRMA-affected dogs together, we identified two regions with multiple 
associated SNPs, one on CFA 28 at 14 Mb (praw= 6.5 x 10
-5
 and pgenome= 0.37) and 
another on CFA 32 at 25 Mb (praw= 7.4 x 10
-5
 and pgenome= 0.40). The latter overlapped 
the peak seen in the analysis of both phenotypes together and reached genome-wide 
significance after correction for stratification (praw= 7.10 x 10
-6
 and pgenome= 0.04), while 







dogs were analysed alone, but did not reach genome-wide significance (praw= 2.1 x 10
-4
 
and pgenome= 0.69) (data not shown). When analysing the Finnish SRMA dogs separately, 
genome-wide significance was found for a single SNP on CFA 30 at 29 Mb (praw= 6.7 x 
10
-6
 and pgenome= 0.03). 
Table 13 Results of the genome-wide association and finemapping studies using 81 affected 





GWA=genome-wide association analysis. The sizes of the associated regions are based on the 
fine-mapping data within the breed complemented with the areas of haplotype-sharing across 
breeds. 
5.2.2 Fine-mapping 
To replicate and narrow down the associated regions, we performed fine-mapping with 
additional samples and 822 SNPs. The average density of SNPs was one SNP/10 Kb. We 
used a total of 425 NSDTRs, 81 IMRD-affected, of which 32 tested ANA-positive, 78 
SRMA-affected, 43 AD-affected, 20 CLT-affected and 203 healthy controls. Additional 
breeds were used to identify shared haplotypes between the breeds, which are expected to 
be much shorter than within a breed. To analyse ANA-positive IMRD, GSDs and cocker 
spaniels were included, and to analyse SRMA Boxers and Petite Basset Griffon Vendeen 
were included (Table 4).  
Fine-mapping data obtained from IMRD- and SRMA-affected dogs and their healthy 
controls were analysed in three groups: dataset 1 (dogs included in GWA, n = 138), 
dataset 2 (additional NSDTRs, including related individuals, n = 186) and a combined 
dataset (datasets 1 and 2, n = 324).  
Two of the loci associated with both sub-phenotypes, CFA 8 and CFA 32. P-values 





 and 2.4–3.4, respectively. The CFA 32 locus remained at approximately the same 
strength and is still relatively large with three signals across a 1.6-Mb region. The CFA 32 
locus contains three relevant candidate genes (DAPP1, PPP3CA and BANK1); BANK1 has 
previously been associated with human SLE 
104
. Other genes within the CFA 32 locus 




include MAP2K1IP1, DNAJB14, H2AFZ, RPS23, DDIT4L, EMCN, RPS24 and RPS17. 
The locus in CFA 8 contains the genes SNRPE and VRK1 and four SNPs with a 97-kb 
haplotype were shared between Boxers and Petit Basset Griffon Vendeens affected with 
SRMA. 
When analysing the ANA-positive dogs alone, three of the four peaks showed an even 




 for the 





). The strongest association was found on CFA 11, which contains a highly 
associated 124-kb five-SNP haplotype in NSDTR and a 127-kb shared haplotype between 
NSDTR, GSD and Cocker Spaniel (CS) cases. This locus contains the genes EPB41L4B, 
C9orf4 and PTPN3. The second best association is found on CFA 24, containing a seven-
SNP 96-kb haplotype in NSDTR and a 127-kb shared haplotype between NSDTR, GSD 
and CS cases. This candidate locus contains six genes, AK128395, WFDC10B, WFDC13, 
AY372174, WFDC1 and DNTTIP1. The association on chromosome 3 includes a two-SNP 
113-kb haplotype in NSDTR and a 256-kb shared haplotype between NSDTRs, GSDs and 
CSs. This locus contains seven genes, AK126887, AP3B2, SCARNA15, FSD2, RPL23A, 









Characterization of the genetic background behind canine SLE-related disease, AD and 
CSK, will likely reveal novel genes and pathways and help to elucidate the aetiology of 
the diseases. It will also establish clinically relevant large animal models for human 
studies in canine breeds, and gene discovery would enable development of new gene tests 
to assist in breeding plans.  
Given the major role of the MHC II in human autoimmune disorders, we strongly 
suspected an influence of the DLA region behind the aetiology of these canine diseases 
and chose to perform a candidate gene study to see if this was the case. We also aimed to 
prove the dog’s power in genome-wide studies since it had been hypothesized that the 
unique breed and genome structure of dog would simplify association studies also in 
complex diseases. The dog genome sequence was published in 2005 and the first 
microarrays were launched in 2007, and we were fortunate to be among the first 
researchers to whom these tools were available.  
No genetic risk factors have previously been identified behind any of the canine 
diseases in this study. Our findings support the suspected autoimmune origin of all 
diseases investigated, as the associations were identified with genes strongly linked with 
autoimmune diseases in humans and dogs and with genes functioning in potential 
immunological pathways. 
6.1 Genetic diversity and population structure indicate narrow 
genetic diversity in GSDs and NSDTRs 
The distribution and frequencies of the DLA-DRB1, -DQA1 and -DQB1 alleles and 
haplotypes vary between breeds. Some alleles may be breed-specific or limited to a few 




Considering the population history, we observed an expected number of haplotypes in 
NSDTRs, which were unevenly distributed. The level of genetic diversity is lower in this 
breed than that found in many other dog breeds 
106
. We identified five DLA-DRB, four 
DLA-DQA1 and five DLA-DQB1 alleles, which formed seven different haplotypes. Two 
of the most common haplotypes were seen in very high frequencies in both Scandinavian 
and American study populations, consisting together of 74.4% and 54.4% of all 
haplotypes, respectively. The third and fourth common haplotypes were seen in moderate 
frequencies in both populations, and the fifth in American dogs. The rest were extremely 
rare and seen in only a few dogs. There was a clear difference in the haplotype frequencies 
between North-American and Scandinavian dogs. Finnish and Swedish dogs showed a 
more similar distribution of haplotypes. The samples had been selected for a disease 
association study and were not therefore ideal for population diversity studies. In addition, 
in AD study we used also discordant sib-pairs as healthy controls. Larger number of 
unrelated individuals should be genotyped to evaluate the DLA polymorphism in 
American NSDTRs more accurately. Both the history and pedigree information suggest 




that today’s NSDTRs are one population, but during the last three decades, the 
subpopulations in different countries have diverged in different directions. MHC studies 
show that MHC haplotypes do not differ between countries, but a slight difference exists 
in haplotype frequencies. In addition, the MDS plot based on genome-wide genotyping 
indicates that breeds on different continents have become differentiated to some degree.  
The situation was better for GSDs, but as it is one of the most common breeds in the 
world, one might have expected to see more genetic diversity. The study population was, 
however, much smaller, but our objective was to explore the association with a disease 
phenotype, not to study the diversity in the breed. Unrelated population controls were 
used, giving a wider perspective to the diversity than could be seen by using discordant 
sib-pairs. Still, the Finnish data is biased by half of the dogs being selected for being 
affected with CSK. The data provided by Lorna Kennedy show 10 haplotypes considered 
typical for the breed and an additional 21 haplotypes common in other breeds but seen in 
only a few GSDs and could therefore be descendant from breed-crosses (Table 14). The 
haplotypes were unevenly distributed, which is commonly seen in pure-bred dogs and 



































Table 14 Haplotype frequencies of 322 German Shepherd Dogs with mainly European 
origin (Lorna Kennedy, personal communication). 







01101 00201 01302 332 245 36,9 196 59,0 49 14,8
01501 00601 00301 332 141 21,2 119 35,8 22 6,6
00101 00101 00201 332 70 10,5 66 19,9 4 1,2
00102 00101 00201 332 46 6,9 43 13,0 3 0,9
01501 00601 02301 332 43 6,5 39 11,7 4 1,2
01201 00401 013017 332 25 3,8 23 6,9 2 0,6
00201 00901 00101 332 14 2,1 13 3,9 1 0,3
01502 00601 02301 332 14 2,1 13 3,9 1 0,3
01502 00601 00301 332 10 1,5 10 3,0 0 0,0
00601 005011 00701 332 8 1,2 7 2,1 1 0,3







00202 00901 00101 332 5 0,8 5 1,5 0 0,0
02001 00401 01303 332 5 0,8 5 1,5 0 0,0
00401 00201 01501 332 4 0,6 4 1,2 0 0,0
01201 00401 01303 332 4 0,6 2 0,6 2 0,6
00102 00101 00802 332 3 0,5 3 0,9 0 0,0
01101 00201 01303 332 3 0,5 3 0,9 0 0,0
01104 00201 01302 332 3 0,5 3 0,9 0 0,0
04001 01001 01901 332 3 0,5 3 0,9 0 0,0
01801 00101 00802 332 3 0,5 2 0,6 1 0,3
00601 00401 01303 332 2 0,3 2 0,6 0 0,0
01601 00101 00201 332 2 0,3 2 0,6 0 0,0
01501 00601 02201 332 2 0,3 1 0,3 1 0,3
00801 00301 00401 332 1 0,2 1 0,3 0 0,0
00901 00101 008011 332 1 0,2 1 0,3 0 0,0
01201 00101 00201 332 1 0,2 1 0,3 0 0,0
01501 00901 00101 332 1 0,2 1 0,3 0 0,0
01501 00601 01901 332 1 0,2 1 0,3 0 0,0
01501 00601 05401 332 1 0,2 1 0,3 0 0,0
02001 00401 01302 332 1 0,2 1 0,3 0 0,0
02301 00301 00501 332 1 0,2 1 0,3 0 0,0
04801 00402 02301 332 1 0,2 1 0,3 0 0,0
Haplotypes considered specific for GSDs
Haplotypes considered to present GSD crossbreeds
Homozygous dogs 
No.    +     %
Homozygous dogs 
No.    +     %
 
6.2 MHC class II is a major genetic risk factor also in canine 
autoimmune diseases, proving the autoimmune origin 
MHC class II gene region is the major risk locus in human autoimmune disorders and has 
been associated with several autoimmune disorders also in domestic dogs. The DLA 
associations of IMRD, CSK and AD combined with previous reports provide strong 
evidence for DLA class II being the major risk locus in canine autoimmunity. Table 15 
lists all reported MHC class II associations with canine autoimmune disorders. 
The risk haplotype for IMRD in NSDTRs is present in 45% in the overall study 
population, being the most common haplotype. The frequency among the control dogs is 
slightly over 30% in each country. The risk haplotype has also been found in six other 




breeds: Alaskan malamute, Labrador retriever, Newfoundlander, golden retriever, Cavalier 
King Charles spaniel and Cocker spaniel 
106
. A similar haplotype, differing only by a 
DLA-DQB1 allele, has been shown to predispose to immune-mediated haemolytic 
anaemia in a combined dataset of different breeds 
30
. The DLA-DRB1 allele in IMRD risk 
haplotype has been found in 100% of the Dobermans affected with Doberman hepatitis 
107
 
The risk haplotype for AD is the second most common haplotype in NSDTRs 
worldwide, present in over 40% of the dogs. The AD risk haplotype has recently been 
shown to be protective against NME in pug dogs 
108
 and shares a DQA1 allele with the 
CSK risk haploype (Study I). In addition, it has previously been associated with a slightly 
increased risk for diabetes and a similar haplotype carrying the same DRB1- and DQA1 




It remains to be seen whether DR or DQ or both are the actual genetic risk factors for 
IMRD and AD. The high frequency of both risk haplotypes in NSDTRs is problematic 
because removal of breeding animals carrying this haplotype would create a serious 
genetic bottleneck, which would severely threaten the viability of the breed. A careful 
planning in breeding, including exclusion of the affected individuals from breeding and 
avoiding production of litters with puppies homozygous for the risk haplotype, is the only 
solution, unless breed-crosses are considered. Increasing the frequency of the rare 
haplotypes might be an option, but there is of course no knowledge of either their 
protective or disease-causing associations. The MHC class II haplotypes are not the only 
genetic risk factors behind these autoimmune disorders, although the DLA gene region is 




























Table 15 All reported DLA-DRB1, DQB1 and DQA1 associations with canine autoimmune 
disorders, including our results. 
 
CSK=chronic superficial keratitis, AF=anal furunculosis, IMRD=immune-mediated rheumatic 
disease, ANA=antinuclear antibody, AD=Addison’s disease, CLT=canine lymphocytic thyroiditis, 
IMHA=immune mediated hemolytic anemia, CRA=canine rheumatic arthritis, NME=necrotizing 
meningoencephalitis, VHK-like syndrome=Vogt-Koyanaki-Harada-like syndrome, JGD=juvenile 
generalized demodicosis, SLO=symmetrical lupoid onychodystrophy, GSD=german shepherd, 
NSDTR=Nova Scotia Duck Tolling Retriever, GS=giant schnauzer. 




The MHC class II risk haplotype for CSK in GSDs is the second most common 
haplotype in the breed. This genetic association with the DLA gene region supports the 
previous clinical, histological and pharmacological studies of CSK as an immune-
mediated disease 
20,41,87,89
. The third common haplotype has previously been associated 
with AF in GSDs and has no common alleles with the CSK risk haplotype. Table 14 
displays the haplotype frequencies of 322 mostly European GSDs, and the risk haplotype 
is present in over 20% of the dogs. The frequency of the haplotype is over 30% in the 
Finnish study population, which reflects the study design, half of the dogs being affected 
with the associated disease. The risk haplotype has been found in 18 other breeds, but at a 
much lower frequency 
106
. Any breed can be affected with CSK, but whether this risk 
haplotype contributes to the disease risk in any other breed has not been examined. 
The DLA-DRB1*015/DQA1*006/DQB1*023 haplotype has previously been 
associated with canine diabetes in the Samoyed, Cairn terrier and Tibetan terrier 
27
. The 
CSK risk haplotype differs from the diabetes haplotype at the DLA-DQB1 locus, although 
DLA-DRB1 was not characterized in as much detail as in our study. The three DLA-
DRB1*015 alleles differ from each other by one nucleotide. The DLA-
DRB1*015/DQA1*00601/DQB1*00301 haplotype has been associated with canine 
IMHA in English Springer Spaniels 
30
. As in the diabetes study, the first allele was not 
characterized in detail and the association was lost when using breed-matched controls. 
The AD risk haplotype in NSDTRs has the same DLA-DQA1 allele, while there is a 
difference of one amino acid in the DLA-DRB1. In addition, the DRB1 allele in CSK risk 
haplotype is shared with the protective Doberman hepatitis haplotype, and together with 
the DQA1 allele with the protective NME haplotype in pugs. 
6.3 Homozygosity of the MCH class II risk haplotype increases 
the risk for autoimmune diseases – mechanism? 
Dogs carrying two copies of the risk haplotype were observed to have an elevated risk of 
developing the disease. In IMRD dogs, the risk was nearly fivefold, in ANA positive 
IMRD dogs over sevenfold, in AD dogs nearly ninefold and in CSK-affected dogs 8.5-
fold. These ORs are among the highest risks reported for an autoimmune disease and 
MHC class II 
54
. The risks calculated for AD and CSK dogs are estimates, since there were 
no control dogs homozygous for the risk haplotype. Low number of samples may also 
affect the OR estimate calculated by using pseudocount. Increased risk with homozygosity 
for risk haplotype has previously been shown with AF in GSDs and with necrotizing 
meningoencephalitis (NME) in pug dogs 
25,108
. In addition, two recent studies have shown 
a stronger susceptibility for a homozygosity for a DLA risk haplotype, one with 
Doberman hepatitis 
107
 and the other with symmetrical lupoid onychodystrophy (SLO) in 
Gordon Setters 
109
. In humans, a dose effect of HLA-DRB1*1501 has been observed in 
susceptibility of multiple sclerosis in two different studies and an HLA-DQB1*02 dose 
effect in coeliac disease 
110-112
. Also, the HLA-DRB1 gene has been associated with 
susceptibility, severity and progression of disease in rheumatoid arthritis 
113
. 
The mechanism of dose effect remains to be solved, but different theories have been 







outside the MHC region might contribute to the disease risk. The MHC region is full of 
immunologically important genes, which might affect, for example the cytokine profile, 
thereby creating an advantageous environment for loss of peripheral tolerance. 
A homozygous disadvantage is a disputed theory, as many believe that it is the 
presence rather than the number of an MHC allele that causes the effect. However, a 
homozygous disadvantage of MHC alleles has been observed in both human and canine 
autoimmune diseases. For example, human T1D susceptibility displays unusual patterns of 
inheritance. Protective MHC alleles have been suggested to express a dominant nature and 
susceptibility alleles a recessive inheritance. This difference may be due to the binding 
affinity of the MHC molecules for the -cell antigens so that products of protective alleles 
bind very strongly, thus requiring fewer MHC molecules. MHC molecules coded by 
susceptibility alleles have a low affinity, requiring more molecules to effectively compete 
for binding 
39
. The binding of the MHC molecules coded by the susceptibility alleles then 
leads to the activation of autoreactive T-cells that have escaped negative selection in the 
thymus, which again has been assisted by MHC molecules, and possible onset of 
autoimmune disease. The MHC-assisted T-cell variety could by definition be responsible 
for susceptibility to autoimmune disease together with the peptide presentation properties 
of MHC class II. Therefore, higher levels of surface expression cannot be ruled out as a 
causative factor. Increased MHC class II expression has been observed in CSK, but it 
could also be a secondary effect due to IFN-  production and be related to the 
inflammation itself and be a part of the pathogenesis by elongating it rather than causing 
it. Elevated MHC class II expression has also been observed in endothelial cells in several 
human autoimmune diseases, including RA, SLE, multiple sclerosis and Crohn´s disease 
114
, and it has been shown to correlate with the severity of Doberman hepatitis 
115
.  
The effect of MHC molecules are usually allele or haplotype specific and may be 
predisposing or protective. However, we discovered not only an elevated risk with 
homozygosity for the MHC class II risk haplotype in two of the studies, but also an 
increased risk with homozygous individuals regardless of the DLA haplotype. In our 
knowledge, this phenomenon has not previously been reported in dogs or humans. Even 
isolated human populations are much more heterozygous than dogs, and it is very unlikely 
that this kind of homozygosity effect could be shown in any human population. One 
possible mechanism to explain an increased risk in general DLA-haplotype homozygosity 
is extensive LD in the MHC region, and therefore, homozygosity might uncover recessive 
non-beneficial alleles. The higher risk for homozygousity for risk haplotype indicates that 
it has itself an impact on pathology, as overall homozygosity might reflect the influence of 
neighbouring genes. Overall homozygosity might also reflect the situation in other parts of 
the genome, as the MHC locus is the most polymorphic region in the genome. When there 
is no heterozygosity left in the DLA region, the other parts of the genome are hardly any 
different. Especially when an inbred population is in question, this is likely the situation 
and recessive alleles are uncovered. 
Another mechanism might also be considered. As previously described in the context 
of the hygiene hypothesis, pathogens may mount up protective immune responses, and, as 
the MHC homozygous dogs are able to recognize fewer antigens, it is plausible to 
conclude that this protection is impaired. This would predispose the dogs not only to 
infections, but also to autoimmunity 
62
. This raises a question, if maximum heterozygosity 




in MHC region is optimal within an individual. If this was true, in the evolutionary point 
of view, we would probably see more duplicated genes in MHC region or maybe wider 
repertoire of differently expressed MHC peptides. One could think that maximal MCH 
diversity within individual would be beneficial in fighting infections, but could it also 
mediate an over-reactive immune response, harmful for the individual or increase the 
number of potentially self-reactive T-cells? Some T-cells may also be cross-reactive with 
self antigens and it may not be beneficial to have excess in activated T-cells. Increase in 
MHC diversity within individual might actually also affect the ability to fight infections, if 
an elevated number of expressed MHC molecules decrease the variety of T-cells by 
negative selection. In conclusion, it is likely that the present level of diversity is optimal, 
but the alleles and haplotypes providing best fitness for an individual vary through time 
and place, that is for example changes in the environmental risk factors. At a presence of 
certain pathogen, particular allele in homozygous form might be beneficial, but predispose 
to an autoimmune disease later in life. 
6.4 The shared epitope in DLA-DRB1 allele is an indication of 
rheumatic autoimmune disease 
The DLA-DRB1*00601 allele in the IMRD risk haplotype contains a five-amino-acid-
long epitope RARAA at amino acid positions 70-74. These amino acids are part of the 
DNA segment that encodes the third hypervariable region (HVR-3). HVRs are mainly 
responsible for the peptide recognition and binding properties of the MHC class II 
molecule peptide binding groove. This group of amino acids is called RA shared epitope 
and it is found in all RA risk alleles both in humans and dogs and it is the most significant 
genetic risk factor for RA 
31,114
. A similar epitope (QARAA) is found in the human SLE-
associated HLA-DRB1*1501 allele 
117
. The mechanistic basis of the shared epitope is 
unknown, but effects on arthritogenic antigen presentation and T-cell repertoire selection 
have been proposed. Dose effects of the shared epitope on penetrance and disease severity 
of RA have been shown 
118
. 
Current evidence suggests that glutamine (Q) or arginine (R) at position 70 is critical 
for RA risk, and aspartic acid (D) at that position confers protection 
118
. The epitope in the 
IMRD-associated DLA-DRB1 allele has Q at position 70, therefore fulfilling the criteria 
of being a similar predisposing variant as those increasing the risk for human RA and 
SLE. This leads further supports for a common MHC class II-associated mechanism of 
rheumatoid disease in both humans and dogs. 
6.5 The first successful GWAS in complex diseases of dogs 
identifies several risk loci for autoimmune diseases in NSDTRs 
This was a proof-of-principal study to show the power of the unique canine breed 
structure in GWAS of genetic risk loci in complex diseases. An extensive LD within a 







cases and 100 healthy controls. Several traits have been mapped in canine Mendelian 





 and ectodermal dysplasia 
14
, but this was the first successful GWAS 
regarding polygenic disorders. We identified five loci associated with SLE-related disease 
using only 81 affected dogs and 57 healthy controls. Futher mapping with additional 
genetic markers (822) and in additional samples (n=487) and phenotypes, also from other 
breeds, verified the results and suggests common risk factors as well as disease-specific 
variants that influence the disease course in a systemic or organ-specific direction. 
NSDTRs are strongly predisposed to several autoimmune diseases, such as SLE-
related disease comprising well-characterized sub-phenotypes IMRD and SRMA, and AD 
15,17,18
. The breed history of NSDTRs has had severe genetic bottlenecks, the ultimate 
being the canine distemper virus outbreaks in the early 1900s. Survival of only a few 
breeding individuals has likely accumulated rare recessive risk variants, and the surviving 
dogs may have had over-reactive immune responses capable of overcoming the repeated 
infections. As today’s dogs descend from these survivors, it is clear that they carry the 
same genetic make-up.  
We identified two loci that were associated with more than one phenotype with 
GWAM. The large CFA 32 region is shared between IMRD and SRMA, and it is plausible 
that common autoimmune predisposing loci containing risk factors leading to interruption 
of maintainance of self-tolerance exist. On the other hand, it is possible that the 1.6-Mb 
region contains several loci and variants contributing to different phenotypes. Three 
excellent candidate genes are found in the CFA 32 region: DAPP1, PPP3CA and BANK1. 
BANK1 encodes a B-cell–specific scaffold protein and LYN tyrosine kinase substrate that 
promotes tyrosine phosphorylation of inositol 1,4,5-trisphosphate receptors. A non-
synonymous substitution in the BANK1 gene causes alternative splicing and has been 
associated with human SLE 
104
. Ca(2+)/calmodulin-regulated protein phosphatise 
(calcineurin) is a heterodimer of a Ca(2+)-binding protein (calcineurin B) and a 
calmodulin-binding catalytic subunit (calcineurin A). There are several isoforms of the 
catalytic subunit, derived from alternative splicing of gene products of at least two genes, 
one of which is PPP3CA 
118
. PPP3CA has been shown differential expression in human 
SLE patients compared with controls 
119
. Calcineurin has also been reported to be the 
target of two important immunosuppressive drugs: cyclosporine A and FK506 
120
. The 
third of the top three candidates in the CFA 32 locus is DAPP1 gene, expressed in both T- 
and B-cells, where it leads to an indirect dose-dependent inhibition of TCR- and BCR-
induced activation of the NF-AT pathway 
121,122
.  
The other locus shared with more than one phenotype was on CFA 8. Both SRMA and 
ANA-positive IMRD subphenotypes were associated separately, but not jointly with the 
locus. This might reflect the fact that there are two adjacent loci. When ANA positive 
dogs were analysed alone, the association was seen on the small nuclear ribonucleoprotein 
polypeptide E (SNRPE) gene, and when SRMA dogs were analysed alone, the association 
was between the genes SNRPE and vaccinia-related kinase 1 (VRK1). SNRPE is one of the 
small nuclear ribonucleoprotein complexes (snRNPs) recognized by circulating 
autoantibodies in human SLE. This protein is one of four 'core' proteins associated with all 
known snRNAs in the U family (U1, U2, U4, U5 and U6). VRK1 is a novel serine-
threonine kinase that regulates several transcription factors, including p53. The gene p53 




has been shown to be one the most consistently under-expressed genes in autoimmune 
diseases, causing differential expression of other genes involved in autoimmune disease, 
and is therefore suggested to be central to autoimmunity 
123
. 
ANA-positive dogs were associated with three more loci on CFA 3, 11 and 24 when 
analysed alone. The strongest association was found on CFA 11, which contains several 
genes, including protein-tyrosine phosphatise, non-receptor-type 3 (PTPN3). PTPN3 is 
involved in T-cell activation and belongs to the same family as protein-tyrosine 
phosphatase, non-receptor-type 22 (PTPN22).  PTPN22 is probably the second most 
common genetic risk factor after MHC for many autoimmune diseases in human, 
including SLE 
124
. PTPN3 has not been reported to be involved in autoimmunity, but it is 
thought to inhibit T-cell activation by de-phosphorylating targets involved in TCR 
signalling. The expression of PTPN3 has been shown to reduce activation of reporter 
genes driven by NF-AT 
125
. 
The second best association was found with CFA 24, containing six genes, and the 
third associated region on CFA 3 contains seven genes, HOMER2 appearing the most 
interesting, as it has been reported to act as negative regulator of T-cell activation. In 
addition, Homer -deficient mice are shown to develop an autoimmune-like pathology with 
lymphocyte infiltration and hyperplasia in lymph nodes 
126
. 





) after fine-mapping and odds ratios of 4.5–8. Both loci that were shared 




 and odds 
ratios of 2.4–3.4. According to power calculations, reliable detection of risk factors 
contributing a two- to fourfold increased risk cannot be expected with our sample size, but 
the loci with the highest odds ratios are within the detectable range. The associated regions 
contain relevant candidate genes based on biological function and are all worthy of 
follow-up studies.  
The MHC locus previously associated with IMRD did not show an association here 
(Study III). We had three SNPs in GWAS in this region, from which two were totally 
homozygous in our NSDTR sample and were therefore not informative and the third 
showed very little heterogeneity. This region in general shows extensive polymorphism 
with for instance, 148 DLA-DRB1, 70 DLA-DQA1, and 26 DLA-DQB1 alleles, and it is 
therefore hard to tag with informative markers. 
Based on our results, we hypothesize that IMRD and SRMA are a part of the same 
disease complex and have common as well as sub-phenotype specific risk factors. 
Therefore we examined the affected dogs both as one group and the two sub-phenotypes 
separately. Shared loci with AD suggest a common locus predisposing to autoimmunity. 
6.6 New immunological pathway in SLE  
Three of the associated loci we found contain four genes that regulate the nuclear factor of 
the activated T-cell (NF-AT) signaling pathway. Antigen-specific immune responses are 
initiated by the interaction of the TCR with antigenic peptide bound to MHC proteins on 
the surface of antigen-presenting cells. The shared locus on CFA 32 contains two genes, 







subunit of calcineurin. Calcineurin is the downstream target of intracellular Ca
2+
 signalling 
that follows the T-cell-MHC contact. Also increased translocation of calcineurin-
dependent transcription factor (NF-ATc2) to the nucleus in the early stages of cell 
activation has been observed in human SLE patients 
127
. In addition to their role in T-cell 
activation, NFATc transcription factors also generate peripheral tolerance against self-
antigens mediated by controlling activation-induced cell death and clonal anergy of T-
helper cells and the activity of regulatory T-cells 
128
. DAPP1 is expressed in both T- and 
B-cells, where it leads to an indirect dose-dependent inhibition of TCR- and B-cell 
receptor (BCR) -induced activation of NF-AT 
121,122
. The PTPN3 gene on ANA-positive 
CFA 11 is thought to inhibit this pathway as well, although it has not been associated with 
autoimmunity 
125
. The third inhibitor, scaffold protein competing for binding to NF-AT 
with calcineurin, is found in the ANA-positive locus CFA 3.  
A typical feature of SLE is clinical heterogeneity, resulting in variable disease 
manifestations. When we started in 2007, nine human lupus susceptibility genes had been 
convincingly identified, compared with the more than 30 convincing genetic associations 
known today 
129
. Both adaptive and innate immune systems are involved, producing 
different subphenotypes. Our results indicate strongly involvement of T-cell activation. 
We hypothesize that predisposition to autoimmune diseases in the modern NSDTR may 
be a result of the early NSDTRs’ ability to survive the outbreaks of canine distemper virus 
in the early 1900s. In addition, modern breeding practices may have accumulated certain 
risk factors. All in all, it is clear that there are several predisposing genes or regulatory 
elements that together contribute to development of these autoimmune diseases. The 
causing variants remain to be identified, as does the way they interact and accumulate the 
increasing risk. There may also be other variants with a smaller risk that have escaped our 
study due to the small sample size. In the future, the development of individual drug 
treatments, e.g. cyclosporine plus corticosteroids based on a dog’s particular risk 
genotype, as well as diagnostic tools and gene tests to aid in planning of breeding 
strategies might be possible. 
6.7 The dog is an excellent model for complex genetic studies  
Dogs have been used as models to understand many diseases, as in epilepsy research by 
cloning the first canine epilepsy gene, Epm2b 
130
. Mutations in the same gene were found 
in humans to cause a fatal form of epilepsy, lafora disease. The dog has also been used as 
a model to develop therapies before they are tested in humans, as is being done in the 
canine model of Duchenne muscular dystrophy in golden retrievers 
131
. 
Results of our successful GWAS of complex diseases in dogs proves the value of the 
domestic dog as a disease model for polygenic disorders. Predisposing high-risk mutations 
have accumulated and become relatively common in dog breeds due to several historical 
bottlenecks. While tens of thousands of samples may be needed to map human diseases 
with rare, low-risk variants due to clinical and genetic heterogeneity, this can now be 
performed in a domestic dog with less than 100 cases and 100 controls. Ancient mutations 
originating from ancient dog have been spread in several breeds after breed creation. 




These mutations are still surrounded by very similar DNA segments, and advantage can be 
taken in GWASs of these shared haplotypes surrounding the causative variants. 
Dogs are exposed to the same environmental risk factors and often even share the same 
diet with humans. Therefore dog is an excellent disease model for autoimmune diseases 
common in both species and the findings may help to understand both common biological 
functions and interactions between genes and environment. Identification of new genes 
and pathways involved in canine autoimmune diseases increases our understanding of the 
pathogenesis of immunological disorders both in human and dog. This may open doors for 
novel diagnostics, gene tests, treatment and drug development in both species. In dogs, 
identification of mutations will help to reduce the incidence of the disease in the breed. 
Complex diseases are not easy to eradicate from the breed, but identification of risk 
variants at least provides more tools to accomplish this goal. Autoimmune disorders are 









7 Conclusions and future perspectives 
When I began my work in autumn 2006, I was full of enthusiasm and started literally from 
a clean slate. The canine genetics group was new and I was the first to be employed. I am 
a passionate dog lover, so it was a dream come true to be able to work towards improving 
dogs’ health, not to mention the potential benefits for human welfare.  
We found the first genetic evidence for canine SLE-related disease, AD and CSK. The 
MHC class II was a strong candidate locus based on both human and dog studies, and we 
were able to confirm an association with CSK, AD and IMRD phenotypes. Our results 
suggest in each of these phenotypes that the DLA-DRB1, -DQB1, -DQA haplotypes are a 
major genetic risk factor, but that they are all polygenic disorders with possibly several 
other genes contributing to the development of the disease. 
The development of technology has been rapid in these four years, with all the new 
dog arrays and high-throughput sequencing technologies becoming available. We 
performed the first successful GWAS in canine complex diseases and identified five loci 
that predispose to a SLE-related disease and AD in NSDTRs. Many of these loci are 
involved in a novel T-cell activation pathway. This study proves the strength of disease 
mapping in dogs. The power of the two-stage strategy is based on extensive LD and long 
haplotypes within a breed, and short haplotypes between dog breeds. In addition, a very 
small number of founders during breed creation and subsequent inbreeding have 
accumulated ancient mutations and diseases. Causative mutations may be detected with 
the new genotyping technologies and information provided by the full genome sequence. 
In addition, we have observed a narrow genetic diversity in NSDTRs and GSDs, and a 
clear increase in disease risk in dogs homozygous for the risk haplotypes. Surprisingly, we 
found that overall homozygosity for the MHC class II region is associated with increased 
risk in CSK and AD. The mechanisms behind the involvement of homozygosity in the 
DLA locus remains unknown, but may reflect either the T-cell repertoire or antigen 
presentation or be a consequence of other predisposing genes in LD within the DLA 
region.  
Our results provide tools and information to assist breeding practices and the fight 
against diseases in these breeds as well as important knowledge of the inheritance. 
Hopefully, our future work will provide more accurate knowledge of the pathogenesis by 
detecting the exact causative variants. These findings would open doors for new 
diagnostics, gene tests and drug development in both dogs and humans. 
Our future plans include identification of additional risk factors for CSK in GSDs by 
GWAS. We already have preliminary results connecting the aetiology of AF, EPI and 
CSK based on an association with common SNPs and haplotypes in these three 
autoimmune diseases. As in NSDTRs, it seems that there are indeed common risk factors 
for autoimmune diseases, as well as disease-specific risk factors. We are also interested in 
examining related breeds to see whether the predisposing MHC haplotype is an universal 
risk factor or specific only to CSK in GSDs. 
Future plans for identification of the disease-causing genetic variants in NSDTRs and 
in breeds sharing the associated haplotypes include a hybrid capture and targeted 
resequencing of the associated haplotypes. The full sequence data will provide thousands 
of variants and potential candidate mutations will be prioritized for further evaluation 




based on two criteria: presence on haplotypes shared by individuals of multiple breeds and 
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